CTC Bio

CTC Bio OCF Margin

The Operating Cash Flow Margin of CTC Bio (060590.KQ) as of Oct 28, 2026 is 3.54 %. In the previous year, Operating Cash Flow Margin was 3.11 % — a change of 13.74% (higher).

OCF Margin

3.54 %

YoY

13.74%

Last updated:

Operating Cash Flow Margin of CTC Bio is 2025 3.54 % . Operating Cash Flow Margin of CTC Bio was 2024 3.11 % . It decreases by 13.74% higher compared to the previous year.

The CTC Bio OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2018
-1.79 KRW
Jan 1, 2019
1.23 KRW
Jan 1, 2020
0.39 KRW
Jan 1, 2021
4.60 KRW
Jan 1, 2022
11.03 KRW
Jan 1, 2023
5.96 KRW
Jan 1, 2024
3.11 KRW
Jan 1, 2025
3.54 KRW
The CTC Bio OCF Margin history
YEAROCF MarginYoY
3.54 %+13.74%
3.11 %-47.75%
5.96 %-45.98%
11.03 %+139.71%
4.60 %+1,073.09%
0.39 %-68.12%
1.23 %-168.87%
-1.79 %-889.98%
0.23 %-95.94%
5.57 %+361.42%
1.21 %-523.27%
-0.29 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CTC Bio Stock analysis

What does CTC Bio do? CTC Bio, Inc. generates revenue through the manufacture and sale of pharmaceuticals, including anticancer agents, antibiotics, bone injury treatments, antiulcer agents, and blood flow stimulants. The company also produces veterinary drugs such as vaccines, antibiotics, immune enhancers, enzymes, organic acid, and avian influenza-related agents, alongside animal feed supplements like pigments, kapok seed meal, and sesame meal. Functional food products, including enzymes and lactobacillus for dairy applications, form another revenue stream. The firm distributes these products domestically and internationally, targeting healthcare providers, veterinarians, and food manufacturers. The company's pharmaceutical segment serves medical professionals seeking treatments for cancer, infections, and gastrointestinal issues. Veterinary drug sales cater to animal health practitioners requiring vaccines and antibiotics for livestock. Animal feed supplements are sold to agricultural businesses, while functional food ingredients target dairy producers. CTC Bio, Inc. leverages its in-house pharmaceutical manufacturing technology and know-how to support product development and maintain competitive pricing. Revenue streams include direct sales of pharmaceuticals, veterinary drugs, animal feed supplements, and functional food ingredients. Domestic markets absorb the majority of these products, with international distribution expanding its reach. The company's focus on integrated production of pharmaceuticals, animal health solutions, and functional food components ensures consistent demand across multiple industry segments. CTC Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CTC Bio stock

Operating Cash Flow Margin of CTC Bio is 3.54 % in 2025.

Operating Cash Flow Margin of CTC Bio changed from 3.11 % to 3.54 %, representing a 13.74% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin CTC Bio since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's CTC Bio with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — CTC Bio

All Key Metrics — CTC Bio